Xiang Xu, PhD, DABT

Xiang Xu, PhD, DABT has a diverse work experience spanning over several companies and institutions. In 1994, Xiang Xu started their career as an Attending Pathologist at Anzhen Hospital, where they served until 1996. They then joined the University of California, San Francisco - School of Medicine as a Research Scientist in 2006 and worked there until 2015. Following this, Xiang Xu joined Hangzhou Xiangsheng Pharmaceuticals, Ltd as a Scientist from 2015 to 2019. At Hangzhou Xiangsheng Pharmaceuticals, they contributed to various research projects. In 2019, Xiang Xu started working at Blade Therapeutics as a Scientist, specializing in anti-fibrosis and anti-neurodegenerative disease drug discovery and development. They were involved in a range of responsibilities, including pharmacology studies, biomarker research, drug screening, and toxicity testing. Most recently, in 2022, Xiang Xu joined Nitrase Therapeutics as a Scientist.

Xiang Xu, PhD, DABT has a comprehensive education history in the field of medical and scientific research. Xiang Xu began their academic journey at Xinxiang Medical College, where they earned a Bachelor's degree in Pediatrics medicine and completed a residency program between 1986 and 1991. Subsequently, they pursued a Master's degree in Pathology at TongJi Medical College of HUST from 1991 to 1994, specializing in the study of liver cancer and cirrhosis.

Continuing their academic pursuits, Xiang Xu enrolled at The Hebrew University of Jerusalem from 1996 to 2002 to obtain a Doctor of Philosophy (PhD) in Pharmacology. During this period, their research focused on inflammatory bowel diseases and fibrotic diseases. Building on their successful doctoral studies, Xiang Xu further extended their expertise by embarking on post-doctoral studies at the University of California, San Francisco, from 2002 to 2006. At UCSF, Xiang Xu actively contributed to the study of infectious diseases, immune diseases, inflammatory diseases, and conducted clinical studies.

In addition to their academic qualifications, Xiang Xu has obtained a certification from the American Board of Toxicology, Inc. in the form of the DABT (Diplomate of the American Board of Toxicology). This certification was obtained in November 2022.

Overall, Xiang Xu's rich educational background, comprising a Bachelor's degree, Master's degree, PhD, and post-doctoral studies, equipped them with deep knowledge and expertise in various aspects of medical research, ranging from pediatrics and pathology to pharmacology, immune diseases, and toxicology.